Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors

This is a Phase 1/2, open-label, multi-center study to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of ETX-929 in participants with advanced solid tumors harboring a Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.

Trial Details

NCT ID
NCT07912593
Phase
PHASE1 / PHASE2
Sponsor
Ensem Therapeutics
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • ETX-929 dose escalation
  • ETX-929 dose escalation in combination with cetuximab
Locations (sample)
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Metastatic or locally advanced and unresectable solid tumor that has progressed on or after at least one available therapy.
  • Tumor harboring a KRAS mutation.
  • An ECOG performance status score of 0 or 1.
  • Adequate organ function.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →